GlaxoSmithKline and The Open Innovation Strategy. Marina Shevchenko, Norrina Brown and Hui Tian June 27, 2011. GlaxoSmithKline at a Glance.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Marina Shevchenko, Norrina Brown and Hui Tian
June 27, 2011
We have a challenging and inspiring mission to improve the quality of human life by enabling people to do more, feel better and live longer.
January 2010, GSK announced its new ‘open innovation’ strategy (OIS). The initiative will serve to aid the company in tackling diseases that disproportionately affect poorer nations.
Diseases such as Malaria, Tuberculosis, and HIV/AIDS
To meet GSK strategic objectives
Special Focus on:
Appointed by the board of directors
Responsible for the execution of the organizations strategic operations
2 retired, 1 relocated, 4 left
CEO: Andrew Witty
Chairman in R&D: Moncef Slaoui
Chief Strategic Officer: David Redfern
HR function can greatly benefit from three years Arun Sehgal’sexperience as Director of Global HR Shared services at Gillette.